Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4057 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 39 40 41  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Immunic–LifeCare Partners: investment, 201901–201904 financing round totalling €26.7m incl existing investor LCP 2019-01-07
Immunic–Omega Funds: investment, 201901–201904 financing round totalling €26.7m incl investor Omega Funds 2019-01-07
Immunic–Saxony-Anhalt (govt): investment, 201901–201904 financing round totalling €26.7m incl existing investor IBG 2019-01-07
Immunic–SEVERAL: investment, 201901–201904 financing round €26.7m in connection with reverse merger to list on Nasdaq 2019-01-07
Immunic–Vital Therapeutics: investment, 201901–201904 reverse merger to list on Nasdaq with Vital Therapies renamed Immunic Inc 2019-01-07
Loxo Oncology–Lilly: investment, 201901–201902 acquisition cash tender offer $8b for $235/share 2019-01-07
N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen 2019-01-07
Roche–Exscientia: drug discovery software, 201901– collab up to CHF67m + royalties using Centaur Chemist to design drug candidates 2019-01-07
Biogen–C4 Therapeutics: neurological drugs, 201901– collab strategic up to $415m upfront/milestones discovery small molecues for protein degradation 2019-01-04
Biogen–Skyhawk Therapeutics: neurological drugs, 201901– collab strategic $74m upfront + milestones discovery small molecues using SkySTAR platform 2019-01-04
Medigene–Helmholtz: cell therapy, 201901– license to co-stimulator to enhance TCR therapies for solid tumours from HMGU 2019-01-04
Ribon Therapeutics–Celgene: investment, 201901 financing round Series B totalling $65m incl new + co-investor Celgene Corp 2019-01-04
Ribon Therapeutics–Column Group: investment, 201901 financing round Series B totalling $65m incl existing + co-investor The Column Group 2019-01-04
Ribon Therapeutics–Deerfield: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Deerfield Management 2019-01-04
Ribon Therapeutics–Euclidean Capital: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Euclidean Capital 2019-01-04
Ribon Therapeutics–JnJ: investment, 201901 financing round Series B totalling $65m incl new + co-investorJJDC 2019-01-04
Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund 2019-01-04
Ribon Therapeutics–Osage Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Osage University Partners 2019-01-04
Ribon Therapeutics–SEVERAL: investment, 201901 financing round Series B $65m led by Novartis Venture Fund 2019-01-04
Ribon Therapeutics–Takeda: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Takeda Ventures 2019-01-04
Ribon Therapeutics–US Venture Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor US Venture Partners 2019-01-04
Sophia Genetics–Alychlo: investment, 201901 financing round Series E totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round Series E totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Eurazeo: investment, 201901 financing round Series E totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round Series E totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round Series E $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
Atriva Therapeutics–High-Tech Gründerfonds: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Atriva Therapeutics–MC Services: public relations, 201901 service existent by MC Services 2019-01-03
Atriva Therapeutics–Meneldor: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Atriva Therapeutics–SEVERAL: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Takeda–Rentschler: biologics contract manufacturing, 201901– supply service continued production for Shire in acquired manufacturing site in Milford 2019-01-03
CARB-X–Germany (govt): grant, 201901–202212 BMBF commits €40m over 4 years 2019-01-01
Curetis–Vienna (govt): grant, 201901–202106 co-funding of developm project of Ares Genetics for AMR assay by Vienna Business Agency 2019-01-01
Delfi Diagnostics–Allianz: investment, 2019 seed financing round totalling $5.5m incl co-investor AV8 Ventures 2019-01-01
Delfi Diagnostics–SEVERAL: investment, 2019 seed financing round $5.5m led by Menlo Ventures 2019-01-01
Marinomed–EU (govt): credit, 20901–2027 up to €15m EIB credit 2019–2022 repayable 2024–2027 2019-01-01
Medicomp–KLIFO: investment, 2019 acquisition of Medicomp GmbH by KLIFO A/S 2019-01-01
Blink Biomedical–Valneva: investment, 201812 existing shareholding of 43.3% by Valneva consolidated via equity method 2018-12-31
Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply FIA-MRMS system 2018-12-31
Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply twelve impact-II UHR-QTOF LC-MS/MS systems 2018-12-31
Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply two timsTOF Pro LC/CCS/MS/MS systems 2018-12-31
Murdoch Univ–Bruker: NMR spectrometer, 2018–201909 supply seven Avance IVDr 600 NMR systems 2018-12-31
Qiagen–Formulatrix: digital PCR technology, 201812– acquisition of all dPCR assets of Formulatrix for $125m upfront cash + $135m milestones 2018-12-31
Harpoon Therapeutics–SEVERAL: investment, 201812–201902 IPO $76m at $14/share 2018-12-27
AC Immune–WuXi Pharmatech: biologics contract manfucturing, 201812– collab strategic alliance biologics CDMO with WuXi Biologics 2018-12-19
Amgen–Molecular Partners: cancer immunotherapy, 201812– collab $50m upfront + $497m milestones + royalties ww excl developm + commerc rights to MP0310 2018-12-18
Novartis–Curetis: antibiotics research, 201812– collab Sandoz to use Ares Genetics’ antibiotic resistance database ARESdb 2018-12-18
Versameb–SEVERAL: investment, 201812 closing of seed B financing round brining total capital raised to date to CHF5.3m 2018-12-18
Shire–Rentschler: investment, 201812–201901 acquisition €na of Shire’s manufacturing facility in Milford, MA by Rentschler Biopharma SE 2018-12-17
Noxxon–MC Services: public relations, 201812 service existent by MC Services 2018-12-14
Noxxon–Trophic Communications: public relations, 201812 service existent by Trophic Communications 2018-12-14
Lonza–ERS Genomics: CRISPR technology, 201812– license €na for bioproduction products + services + iPSC research to Lonza Pharma & Biotech 2018-12-13
AC Immune–Lilly: credit, 201812 convertible note $50m in connection with license + collab agreement 2018-12-12
Imprint Analytics–SGS: credit, 201812– convertible loan as part of strategic partnership 2018-12-12
Lilly–AC Immune: tau aggregation inhibitors, 201812– collab + license agreem CHF80m upfront + CHF1.76b milestones + royalties 2018-12-12
SGS–Imprint Analytics: food analysis, 201812– collab strategic partnership isotope analysis for proof of origin + authenticity food testing 2018-12-12
DenovoMatrix–High-Tech Gründerfonds: investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
DenovoMatrix–Saxony (govt): investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
DenovoMatrix–SEVERAL: investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
genOway–Merck (DE): CRISPR technology, 202001– collab strategic alliance extention incl adding non-excl license for all non-rodent animal cell models 2018-12-10
Novartis–Intellia Therapeutics: CRISPR technology, 201812–201912 collab + license agreem expansion incl $10m upfront payment + milestones + royalties 2018-12-06
Merck (DE)–V7: AI software, 201812– collab on software that scientists can use to tag images for future use in training AI software 2018-12-05
Dispendix–Cellink: investment, 201812 acquisition €5m of Dispendix GmbH by Cellink AB 2018-12-01
Resistell–SEVERAL: investment, 201812 seed financing round CHF850k 2018-12-01
Rheostat Therapeutics–SEVERAL: investment, 201811 financing round Series A $23m co-led by MRL Ventures + AbbVie Ventures 2018-11-26
AbbVie–Mission Therapeutics: DUB inhibitors, 201811– collab RnD + license option €na for Alzheimer’s + Parkinson’s diseases 2018-11-15
Cadent Therapeutics–Access Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Access Industries 2018-11-15
Cadent Therapeutics–Atlas Venture: investment, 201811 financing round Series B totalling $40m incl co-lead investor Atlas Venture 2018-11-15
Cadent Therapeutics–Clal Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Clal Biotechnology Industries 2018-11-15
Cadent Therapeutics–Cowen: investment, 201811 financing round Series B totalling $40m incl co-lead investor Cowen Healthcare Investments 2018-11-15
Cadent Therapeutics–Novartis: investment, 201811 financing round Series B totalling $40m incl co-investor Novartis Institutes for Biomedical Research 2018-11-15
Cadent Therapeutics–Qiming: investment, 201811 financing round Series B totalling $40m incl co-investor Qiming Venture Partners 2018-11-15
Cadent Therapeutics–SEVERAL: investment, 201811 financing round Series B $40m co-led by Cowen Healthcare Investments + Atlas Venture 2018-11-15
Virion Biotherapeutics–Trophic Communications: public relations, 201811 service existent by Trophic 2018-11-14
Immunic–Daiichi Sankyo: IMU-856, 201811– license option agreem ww excl to in-license + develop IMU-856 program for IBD 2018-11-05
Psyros Diagnostics–Novartis: point-of-care diagnostics, 201811 acquisition IP + equipment related to Niji point-of-care dx platform from Novartis 2018-11-01
Q-Bioanalytic–Eurofins: investment, 201811 acquisition by Eurofins 2018-11-01
Rheostat Therapeutics–SV Health Investors: investment, <201811 Rheostat incubated + seeded by SV Health Investors + Dementia Discovery Fund 2018-11-01
Galecto–BPCE: investment, 201810 financing round Series C totalling €79m incl new + co-investor Seventure Partners 2018-10-26
XtalPi–SEVERAL: investment, 201810 financing round Series B-1 extension $46m led by China Life Healthcare Fund 2018-10-24
XtalPi–Swiss Investment Group: investment, 201810 financing round Series B-1 extension totalling $46m incl co-investor SIG 2018-10-24
Genome Biologics (DE)–EU (govt): grant, 201810 Horizon 2020 Phase 2 Grant €2.42m 2018-10-22
Kumovis–Ffilipa Venture Capital: investment, 201810 seed financing round totalling 7-digit € incl family office 2018-10-17
Kumovis–High-Tech Gründerfonds: investment, 201810 seed financing round totalling 7-digit € incl investor HTGF 2018-10-17
Kumovis–SEVERAL: investment, 201810 seed financing round 7-digit € from HTGF + Ffilipa Venture Capital 2018-10-17
Atai Life Sciences–SEVERAL: investment, 201810 1st financing round €21.2m from private investors 2018-10-01
Neuron23–SEVERAL: investment, 201810c financing round Series A $33.5m from Westlake Village BioPartners + Kleiner Perkins 2018-10-01
Novaliq–Hopp Group: investment, 201810 financing round €44.9m from Dievini Hopp BioTech Holding GmbH 2018-10-01
Bayer–Inova Software: business development software, 201809 supply existent Bayer is user of Inova Partnering Platform 2018-09-27
Lilly–Inova Software: business development software, 201809 supply existent Lilly is user of Inova Partnering Platform 2018-09-27
Novartis–Inova Software: business development software, 201809 supply existent Novartis is user of Inova Partnering Platform 2018-09-27
Roche–Inova Software: business development software, 201809 supply existent Roche is user of Inova Partnering Platform 2018-09-27
Tolremo Therapeutics–Altos Venture: investment, 201809 financing round Series A totalling CHF9m incl new + co-investor Altos Venture 2018-09-24
Tolremo Therapeutics–BioMedPartners: investment, 201809 financing round Series A totalling CHF9m incl new + lead investor BioMedPartners 2018-09-24
Tolremo Therapeutics–Redalpine: investment, 201809 financing round Series A totalling CHF9m incl new + co-investor Redalpine 2018-09-24
Tolremo Therapeutics–Zürcher Kantonalbank: investment, 201809 financing round Series A totalling CHF9m incl exisintg + co-investor ZKB 2018-09-24
Luciole Medical–Trophic Communications: public relations, 201809 service existent by Trophic Communications 2018-09-17
NeuMoDx–Qiagen: investment, 201809 existent Qiagen owns 19.9% of NeuMoDx 2018-09-17
NeuMoDx–Qiagen: investment, 201809– option to acquire remaining 80.1% of NeuMoDx for $234m 2018-09-17
Qiagen–NeuMoDx: molecular diagnostics, 201809– collab distribution outside US by Qiagen + implementation of Qiagen reagents on NeuMoDex PRC systems 2018-09-17
next pagenext page 1 2 3 ... 39 40 41  next pagenext page



Advertisement

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Swiss Biotech Association LSG Global Village 2025 Basel 650x300px

» top